Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL
The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a Phase Ib/II trial, for the same setting as CAR-T agents.
You may also be interested in...
Pyxis’s $152m Series B Will Push Trio Of ADCs Toward Clinic
Pyxis says its three preclinical ADCs, acquired from Pfizer and LegoChem, offer immunomodulatory effects as well as direct killing of tumor cells. It hopes all three will reach Phase I in 2022.
Roche Pharma Chief Picks Out Pearls in Cancer Pipeline
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.